calpain and pazopanib

calpain has been researched along with pazopanib* in 1 studies

Trials

1 trial(s) available for calpain and pazopanib

Article	Year
Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma. Bulletin of experimental biology and medicine, 2016, Volume: 160, Issue:6 We analyzed the dynamics of the expression of transcription factors, VEGF and its receptor VEGFR2, serine-threonine protein kinase mTOR and activity of proteasome and calpain in patients with metastatic renal cancer during therapy with tyrosine kinase inhibitor Votrient and mTOR blocker Afinitor. The expression of hypoxic nuclear factor HIF-1α in the tumor tissue decreased during therapy with the target preparations. The decrease of VEGF and its receptor VEGFR2 was observed only in patients treated with mTOR inhibitor. The increase in calpain activity in the tumor tissue was observed in both groups. These findings extend our understanding of the mechanism of action of target anticancer preparations as allow considering the studied markers as predictors in choosing optimal therapy. Topics: Antineoplastic Combined Chemotherapy Protocols; Calpain; Carcinoma, Renal Cell; Everolimus; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Nephrectomy; NF-kappa B; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2016

Article

Year

Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma.

Bulletin of experimental biology and medicine, 2016, Volume: 160, Issue:6

We analyzed the dynamics of the expression of transcription factors, VEGF and its receptor VEGFR2, serine-threonine protein kinase mTOR and activity of proteasome and calpain in patients with metastatic renal cancer during therapy with tyrosine kinase inhibitor Votrient and mTOR blocker Afinitor. The expression of hypoxic nuclear factor HIF-1α in the tumor tissue decreased during therapy with the target preparations. The decrease of VEGF and its receptor VEGFR2 was observed only in patients treated with mTOR inhibitor. The increase in calpain activity in the tumor tissue was observed in both groups. These findings extend our understanding of the mechanism of action of target anticancer preparations as allow considering the studied markers as predictors in choosing optimal therapy.

Topics: Antineoplastic Combined Chemotherapy Protocols; Calpain; Carcinoma, Renal Cell; Everolimus; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Nephrectomy; NF-kappa B; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2016